2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2727

BI 695501, a Proposed Biosimilar for Adalimumab, Shows Bioequivalence to Adalimumab Reference Products in a Randomized, Double-Blind Phase I Trial in Healthy Subjects
Abstract Number: 634

Big Data International Primary Sjögren Syndrome Registry: Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria
Abstract Number: 3215

Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
Abstract Number: 1853

Binding of a Novel IgG3 VH4-34 Monoclonal Antibody to ssRNA in SLE
Abstract Number: 270

Biologic Agents in Refractory Adult Still’s Disease: Better Response Rates and Acceptable Safety with Anakinra and Tocilizumab
Abstract Number: 464

Biologic Therapy Treatment Complications in the Alberta Aboriginal Population with Rheumatoid Arthritis
Abstract Number: 617

Biological Down-Titration in RA: Patient Profile and Response to Retreatment in Flaring Patients
Abstract Number: 582

Biological Drugs Dose Tapering in Inflammatory Rheumatic Diseases: 2 Year Results at Basurto University Hospital
Abstract Number: 3126

Biomarkers Associated with Hyperintense White Matter Lesions in Systemic Lupus Erythematosus
Abstract Number: 720

Biomarkers in Lupus Nephritis: The Possible Role of Serum Cystatin C, Serum β2-Microglobulin, Urinary Î±1-Microglobulin and Albuminâ�„Creatinine Ratio
Abstract Number: 1964

Biomarkers in Temporal Artery Biopsies and Sera of Patients with Giant Cell Arteritis
Abstract Number: 722

Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
Abstract Number: 1868

BLK Pathway-Associated rs13277113 GA Genotype Is More Frequent in Systemic Lupus Erythematosus Patients and Associated with Low Gene Expression and Increased Flares
Abstract Number: 1771

Blockade of Immune Complex-Mediated Glomerulonephritis By Highly Selective Inhibition of Bruton’s Tyrosine Kinase
Abstract Number: 2789

Blood and Salivary Gland BAFF-Driven B-Cell Hyperactivity in Rituximab Non-Responder Patients with Primary Sjögren’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].